vs

Side-by-side financial comparison of Cardlytics, Inc. (CDLX) and PRECISION BIOSCIENCES INC (DTIL). Click either name above to swap in a different company.

Cardlytics, Inc. is the larger business by last-quarter revenue ($50.9M vs $34.2M, roughly 1.5× PRECISION BIOSCIENCES INC). On growth, PRECISION BIOSCIENCES INC posted the faster year-over-year revenue change (5261.1% vs -25.5%). Cardlytics, Inc. produced more free cash flow last quarter ($13.0M vs $-11.3M). Over the past eight quarters, PRECISION BIOSCIENCES INC's revenue compounded faster (39.5% CAGR vs -9.6%).

Cardlytics is a leading purchase intelligence and advertising platform that partners with major banks to analyze anonymized consumer transaction data. It delivers targeted, performance-driven ad campaigns for consumer brands, retailers and service providers, helping advertisers reach audiences based on real purchase behavior, with core operations across North America and the United Kingdom.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

CDLX vs DTIL — Head-to-Head

Bigger by revenue
CDLX
CDLX
1.5× larger
CDLX
$50.9M
$34.2M
DTIL
Growing faster (revenue YoY)
DTIL
DTIL
+5286.6% gap
DTIL
5261.1%
-25.5%
CDLX
More free cash flow
CDLX
CDLX
$24.3M more FCF
CDLX
$13.0M
$-11.3M
DTIL
Faster 2-yr revenue CAGR
DTIL
DTIL
Annualised
DTIL
39.5%
-9.6%
CDLX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CDLX
CDLX
DTIL
DTIL
Revenue
$50.9M
$34.2M
Net Profit
$20.1M
Gross Margin
Operating Margin
-12.0%
36.6%
Net Margin
58.9%
Revenue YoY
-25.5%
5261.1%
Net Profit YoY
213.5%
EPS (diluted)
$-0.15
$2.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDLX
CDLX
DTIL
DTIL
Q4 25
$50.9M
$34.2M
Q3 25
$47.0M
$13.0K
Q2 25
$58.0M
$18.0K
Q1 25
$56.4M
$29.0K
Q4 24
$68.3M
$638.0K
Q3 24
$61.1M
$576.0K
Q2 24
$64.0M
$49.9M
Q1 24
$62.2M
$17.6M
Net Profit
CDLX
CDLX
DTIL
DTIL
Q4 25
$20.1M
Q3 25
$-72.7M
$-21.8M
Q2 25
$-9.3M
$-23.5M
Q1 25
$-13.3M
$-20.6M
Q4 24
Q3 24
$-145.2M
$-16.4M
Q2 24
$-4.3M
$32.7M
Q1 24
$-24.3M
$8.6M
Operating Margin
CDLX
CDLX
DTIL
DTIL
Q4 25
-12.0%
36.6%
Q3 25
-146.6%
-158976.9%
Q2 25
-22.0%
-121538.9%
Q1 25
-24.9%
-76248.3%
Q4 24
-12.2%
Q3 24
-243.1%
-3693.6%
Q2 24
-24.7%
48.4%
Q1 24
-36.7%
-23.8%
Net Margin
CDLX
CDLX
DTIL
DTIL
Q4 25
58.9%
Q3 25
-154.7%
-167476.9%
Q2 25
-16.0%
-130666.7%
Q1 25
-23.5%
-70913.8%
Q4 24
Q3 24
-237.6%
-2851.6%
Q2 24
-6.7%
65.6%
Q1 24
-39.0%
48.8%
EPS (diluted)
CDLX
CDLX
DTIL
DTIL
Q4 25
$-0.15
$2.62
Q3 25
$-1.36
$-1.84
Q2 25
$-0.18
$-2.13
Q1 25
$-0.26
$-2.21
Q4 24
$-0.36
Q3 24
$-2.90
$-2.25
Q2 24
$-0.09
$4.67
Q1 24
$-0.56
$1.70

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDLX
CDLX
DTIL
DTIL
Cash + ST InvestmentsLiquidity on hand
$48.7M
$115.6M
Total DebtLower is stronger
$212.6M
Stockholders' EquityBook value
$-6.5M
$92.2M
Total Assets
$285.6M
$154.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDLX
CDLX
DTIL
DTIL
Q4 25
$48.7M
$115.6M
Q3 25
$44.0M
$44.9M
Q2 25
$46.7M
$62.2M
Q1 25
$52.0M
$77.2M
Q4 24
$65.6M
$86.3M
Q3 24
$67.0M
$101.2M
Q2 24
$71.2M
$123.6M
Q1 24
$97.8M
$137.8M
Total Debt
CDLX
CDLX
DTIL
DTIL
Q4 25
$212.6M
Q3 25
$214.6M
Q2 25
$214.3M
Q1 25
$213.9M
Q4 24
$213.6M
Q3 24
$213.2M
Q2 24
$212.9M
Q1 24
$257.9M
Stockholders' Equity
CDLX
CDLX
DTIL
DTIL
Q4 25
$-6.5M
$92.2M
Q3 25
$-4.7M
$16.6M
Q2 25
$58.7M
$34.1M
Q1 25
$64.1M
$49.3M
Q4 24
$70.0M
$56.4M
Q3 24
$69.7M
$64.9M
Q2 24
$210.0M
$74.7M
Q1 24
$199.1M
$37.2M
Total Assets
CDLX
CDLX
DTIL
DTIL
Q4 25
$285.6M
$154.4M
Q3 25
$292.8M
$93.5M
Q2 25
$361.1M
$108.9M
Q1 25
$369.1M
$124.4M
Q4 24
$392.7M
$136.4M
Q3 24
$399.4M
$153.3M
Q2 24
$534.4M
$165.8M
Q1 24
$569.0M
$184.7M
Debt / Equity
CDLX
CDLX
DTIL
DTIL
Q4 25
Q3 25
Q2 25
3.65×
Q1 25
3.34×
Q4 24
3.05×
Q3 24
3.06×
Q2 24
1.01×
Q1 24
1.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDLX
CDLX
DTIL
DTIL
Operating Cash FlowLast quarter
$13.0M
$-11.3M
Free Cash FlowOCF − Capex
$13.0M
$-11.3M
FCF MarginFCF / Revenue
25.5%
-32.9%
Capex IntensityCapex / Revenue
0.0%
0.1%
Cash ConversionOCF / Net Profit
-0.56×
TTM Free Cash FlowTrailing 4 quarters
$8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDLX
CDLX
DTIL
DTIL
Q4 25
$13.0M
$-11.3M
Q3 25
$1.8M
$-15.3M
Q2 25
$1.2M
$-20.3M
Q1 25
$-6.7M
$-19.1M
Q4 24
$3.0M
$-58.4M
Q3 24
$1.4M
$-5.9M
Q2 24
$4.4M
$-14.9M
Q1 24
$-17.6M
$-19.0M
Free Cash Flow
CDLX
CDLX
DTIL
DTIL
Q4 25
$13.0M
$-11.3M
Q3 25
$1.7M
Q2 25
$903.0K
$-20.3M
Q1 25
$-6.8M
$-19.1M
Q4 24
$2.9M
$-58.7M
Q3 24
$878.0K
$-6.0M
Q2 24
$4.1M
$-14.9M
Q1 24
$-18.3M
$-19.1M
FCF Margin
CDLX
CDLX
DTIL
DTIL
Q4 25
25.5%
-32.9%
Q3 25
3.7%
Q2 25
1.6%
-112627.8%
Q1 25
-12.1%
-65917.2%
Q4 24
4.2%
-9199.8%
Q3 24
1.4%
-1033.2%
Q2 24
6.5%
-29.9%
Q1 24
-29.4%
-108.4%
Capex Intensity
CDLX
CDLX
DTIL
DTIL
Q4 25
0.0%
0.1%
Q3 25
0.0%
0.0%
Q2 25
0.6%
11.1%
Q1 25
0.2%
220.7%
Q4 24
0.2%
39.2%
Q3 24
0.8%
6.8%
Q2 24
0.4%
0.1%
Q1 24
1.0%
0.5%
Cash Conversion
CDLX
CDLX
DTIL
DTIL
Q4 25
-0.56×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-0.45×
Q1 24
-2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons